Nano-anticancer promise in Phase II ovarian cancer trial
CRLX101, Cerulean Pharma's investigational 'nanopharmaceutical' has met its primary efficacy endpoint in an ongoing single-arm Phase II monotherapy trial in relapsed ovarian cancer.
CRLX101, Cerulean Pharma's investigational 'nanopharmaceutical' has met its primary efficacy endpoint in an ongoing single-arm Phase II monotherapy trial in relapsed ovarian cancer.